Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

PRLD 11.27.2024

Full Press ReleaseSEC FilingsOur PRLD Tweets

About Gravity Analytica

Recent News

  • 12.11.2024 - Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
  • 12.10.2024 - Preliminary Results of a Phase 1, Dose‑Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, as Monotherapyand in Combination With Zanubrutinib in Patients With Relapsed / Refractory Lymphoid Malignancies
  • 12.10.2024 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Cancer Cell Death in Preclinical Models of Acute Myeloid Leukemia

Recent Filings

  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.11.2024 - 8-K Current report
  • 12.11.2024 - EX-99.1 EX-99.1

WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) --Prelude Therapeutics Incorporated(Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024.

On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website underEvents and Presentations. The recording will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.

Investor Contact:Robert DoodySenior Vice President, Investor RelationsPrelude Therapeutics484.639.7235RDoody@preludetx.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com